Ozempic (semaglutide) is a GLP-1 receptor agonist administered subcutaneously for type 2 diabetes mellitus in the UK
Diabetol Metab Syndr 9(1):101 Archundia-Herrera C, Macias-Cervantes M, Ruiz-Muoz B, Vargas-Ortiz K, Kornhauser C, Perez-Vazquez V (2017) Muscle irisin response to aerobic vs HIIT in overweight female adolescents
Why Losing Weight Without Protecting Muscle Can Backfire Weight loss is not automatically healthy if the body loses the wrong type of tissue
Opciones aprobadas actualmente disponibles incluyen: Inyecciones subcutneas semanales o diarias de GLP-1 RA Semaglutida oral (Rybelsus) para diabetes tipo 2 Programas de soporte al paciente que facilitan la tcnica de inyeccin Los profesionales de salud deben advertir a los pacientes sobre productos no regulados que afirman ofrecer beneficios similares a medicamentos GLP-1 aprobados
The business model incentivizes recruitment and sales volume, not necessarily clinical outcomes
"We expected there might be some stigma around using a GLP-1," Erin Standen, assistant professor of psychological sciences at Rice University, said in a statement